232 related articles for article (PubMed ID: 38230523)
1. X-linked hypophosphatemia, fibroblast growth factor 23 signaling, and craniosynostosis.
Grimbly C; Graf D; Ward LM; Alexander RT
Exp Biol Med (Maywood); 2023 Nov; 248(22):2175-2182. PubMed ID: 38230523
[TBL] [Abstract][Full Text] [Related]
2. X-linked hypophosphatemia and growth.
Fuente R; Gil-Peña H; Claramunt-Taberner D; Hernández O; Fernández-Iglesias A; Alonso-Durán L; Rodríguez-Rubio E; Santos F
Rev Endocr Metab Disord; 2017 Mar; 18(1):107-115. PubMed ID: 28130634
[TBL] [Abstract][Full Text] [Related]
3. X-linked hypophosphatemic rickets and sagittal craniosynostosis: three patients requiring operative cranial expansion: case series and literature review.
Jaszczuk P; Rogers GF; Guzman R; Proctor MR
Childs Nerv Syst; 2016 May; 32(5):887-91. PubMed ID: 26510652
[TBL] [Abstract][Full Text] [Related]
4. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
Kinoshita Y; Fukumoto S
Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
[TBL] [Abstract][Full Text] [Related]
5. Iron replacement ameliorates hypophosphatemia in autosomal dominant hypophosphatemic rickets: A review of the role of iron.
Menon LP; Weinstein RS
Bone; 2020 Feb; 131():115137. PubMed ID: 31756522
[TBL] [Abstract][Full Text] [Related]
6. Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism.
Gattineni J; Baum M
Pediatr Nephrol; 2010 Apr; 25(4):591-601. PubMed ID: 19669798
[TBL] [Abstract][Full Text] [Related]
7. The changing face of hypophosphatemic disorders in the FGF-23 era.
Lee JY; Imel EA
Pediatr Endocrinol Rev; 2013 Jun; 10 Suppl 2(0 2):367-79. PubMed ID: 23858620
[TBL] [Abstract][Full Text] [Related]
8. Approach to Hypophosphatemic Rickets.
Ackah SA; Imel EA
J Clin Endocrinol Metab; 2022 Dec; 108(1):209-220. PubMed ID: 35981346
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of FGFR Signaling Partially Rescues Hypophosphatemic Rickets in HMWFGF2 Tg Male Mice.
Xiao L; Du E; Homer-Bouthiette C; Hurley MM
Endocrinology; 2017 Oct; 158(10):3629-3646. PubMed ID: 28938491
[TBL] [Abstract][Full Text] [Related]
10. Phosphatonins: From Discovery to Therapeutics.
Kritmetapak K; Kumar R
Endocr Pract; 2023 Jan; 29(1):69-79. PubMed ID: 36210014
[TBL] [Abstract][Full Text] [Related]
11. Characterization of otologic involvement in patients with X-Linked Hypophosphatemia.
Ivanovic-Zuvic D; Santander MJ; Jiménez M; Novoa I; Winter M; Florenzano P
Clin Otolaryngol; 2021 Nov; 46(6):1251-1256. PubMed ID: 34170626
[No Abstract] [Full Text] [Related]
12. The first Korean case report with scaphocephaly as the initial sign of X-linked hypophosphatemic rickets.
Lee KS; Lee BL
Childs Nerv Syst; 2019 Jun; 35(6):1045-1049. PubMed ID: 30613854
[TBL] [Abstract][Full Text] [Related]
13. Early Discrimination Between Tumor-Induced Rickets/Osteomalacia and X-Linked Hypophosphatemia in Chinese Children and Adolescents: A Retrospective Case-Control Study.
Jiajue R; Ni X; Jin C; Huo L; Wu H; Liu Y; Jin J; Yu W; Lv W; Zhou L; Xia Y; Chi Y; Cui L; Pang Q; Li X; Jiang Y; Wang O; Li M; Xing X; Meng X; Xia W
J Bone Miner Res; 2021 Sep; 36(9):1739-1748. PubMed ID: 33971042
[TBL] [Abstract][Full Text] [Related]
14. Hypophosphatemia and growth.
Santos F; Fuente R; Mejia N; Mantecon L; Gil-Peña H; Ordoñez FA
Pediatr Nephrol; 2013 Apr; 28(4):595-603. PubMed ID: 23179196
[TBL] [Abstract][Full Text] [Related]
15. Craniosynostosis as the Presenting Feature of X-linked Hypophosphatemic Rickets.
Vakharia JD; Matlock K; Taylor HO; Backeljauw PF; Topor LS
Pediatrics; 2018 Apr; 141(Suppl 5):S515-S519. PubMed ID: 29610183
[TBL] [Abstract][Full Text] [Related]
16. Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders.
Ramos P; Larson B; Ashrafzadeh-Kian S; Ito N; Kato H; Bornhorst JA; Algeciras-Schimnich A
Endocr Pract; 2023 Mar; 29(3):193-198. PubMed ID: 36627024
[TBL] [Abstract][Full Text] [Related]
17. Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice.
Murali SK; Andrukhova O; Clinkenbeard EL; White KE; Erben RG
PLoS Biol; 2016 Apr; 14(4):e1002427. PubMed ID: 27035636
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries.
Al Juraibah F; Al Amiri E; Al Dubayee M; Al Jubeh J; Al Kandari H; Al Sagheir A; Al Shaikh A; Beshyah SA; Deeb A; Habeb A; Mustafa M; Zidan H; Mughal MZ
Arch Osteoporos; 2021 Mar; 16(1):52. PubMed ID: 33660084
[TBL] [Abstract][Full Text] [Related]
19. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
Athonvarangkul D; Insogna KL
Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
[TBL] [Abstract][Full Text] [Related]
20. Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD.
Perwad F; Portale AA
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1097-1099. PubMed ID: 31171590
[No Abstract] [Full Text] [Related]
[Next] [New Search]
